Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis

Clinical and Experimental Immunology

Volumn 136, Issue 2, 2004, Pages 388-392

  Hebbar, M ^a   Jeannin, P ^b   Magistrelli, G ^b   Hatron, P Y ^a   Hachulla, E ^a   Devulder, B ^a   Bonnefoy, J Y ^b   Delneste, Y ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Sj gren's syndrome; Soluble CD28; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

CD28 ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY CD3; RECOMBINANT ANTIGEN;

ADOLESCENT; ADULT; AGED; ANTIGEN DETECTION; ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVITY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SJOEGREN SYNDROME; SOLUBILITY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

EID: 2142705256     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02427.x     Document Type: Article

References (44)

1. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 1997; 9:396-404.
2. Greenfield EA, Nguyen KA, Kuchroo VK. CD28/B7 costimulation: a review. Crit Rev Immunol 1998; 18:389-418.
3. Ledbetter JA, Martin PJ, Spooner CE, Wofsy D, Tsu TT, Beatty PG, Gladstone P. Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T cells. J Immunol 1985; 135:2331-6.
4. Linsley PS, Clark EA, Ledbetter J. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990; 87:5031-5.
5. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993; 366:76-9.
6. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulaiton. Proc Natl Acad Sci USA 1993; 90:6586-90.
7. Noel PJ, Boise LH, Green JM, Thompson CB. CD28 costimulation prevents cell death during primary T cell activation. J Immunol 1996; 157:636-42.
8. Shahinian A, Pfeffer K, Lee KP et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261:609-12.
9. Mages HW, Hutloff A, Heuck C, Buchner K, Himmelbauer H, Oliveri F, Kroczek RA. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur J Immunol 2000; 30:1040-7.
10. Ling V, Wu PW, Finnerty HF et al. Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J Immunol 2000; 164:1653-7.
11. Chapoval AI, Ni J, Lau JS et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2:269-74.
12. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34.
13. Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2000; 2:261-8.
14. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA. ICOS is an inducible T-cell costimulator structurally and functionally related to CD28. Nature 1999; 397:263-6.
15. Yoshinaga SK, Whoriskey JS, Khare SD et al. T-cell costimulation through B7RP-1 and ICOS. Nature 1999; 402:827-32.
16. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 family: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001; 2:203-9.
17. Magistrelli G, Jeannin P, Elson G, Gauchat JF, Nguyen TN, Bonnefoy JY, Delneste Y. Identification of three alternatively spliced variants of human CD28 mRNA. Biochem Biophys Res Commun 1999; 259:34-7.
18. Magistrelli G, Jeannin P, Herbault N, Benoit de Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by non stimulated human T cells. Eur J Immunol 1999; 29:3596-602.
19. Oaks MK, Hallett KM. Cutting edge, a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000; 164:5015-8.
20. Jeannin P, Magistrelli G, Aubry JP et al. Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity 2000; 13:303-12.
21. Horwitz DA, Tang FL, Stimmler MM, Oki A, Gray JD. Decreased T cell response to anti-CD2 in systemic lupus erythematosus and reversal by anti-CD28: evidence for impaired T cell-accessory cell interaction. Arthritis Rheum 1997; 40:822-33.
22. Miyasaka N, Murota N, Yamaoka K, Sato K, Yamada T, Nishido T, Okuda M. Interleukin 2 defect in the peripheral blood and the lung in patients with Sjogren's syndrome. Clin Exp Immunol 1986; 65:58-66.
23. Miyasaka N, Sauvezie B, Pierce DA, Daniels TE, Talal N. Decreased autologous mixed lymphocyte reaction in Sjögren's syndrome. J Clin Invest 1980; 66:928-33.
24. Abe K, Takasaki Y, Ushiyama C et al. Expression of CD80 and CD86 on peripheral blood T lymphocytes in patients with systemic lupus erythematosus. J Clin Immunol 1999; 19:58-66.
25. Takasaki Y, Ogaki M, Abe K et al. Expression of costimulatory molecule CD80 on peripheral blood T cells in patients with systemic lupus erythematosus. J Rheumatol 1998; 25:1085-91.
26. Schmidt D, Goronzy JJ, Weyand CM. CD4+CD7-CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J Clin Invest 1996; 97:2027-37.
27. Kaneko H, Saito K, Hashimoto H, Yagita H, Okumura K, Azuma M. Preferential elimination of CD28+ T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis. Clin Exp Immunol 1996; 106:218-29.
28. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994; 265:1225-7.
29. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181:1145-55.
30. Chitnis T, Najafian N, Abdullah KA, Dong V, Yaghita H, Sayegh MH, Khoury SJ. CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001; 107:575-83.
31. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 1995; 96:987-93.
32. McHugh RS, Ratnoff WD, Gilmartin R, Sell KW, Selvaraj P. Detection of a soluble form of B7-1 (CD80) in synovial fluid from patients with arthritis using monoclonal antibodies against distinct epitopes of human B7-1. Clin Immunol Immunopathol 1998; 87:50-9.
33. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
34. Bombardieri C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35:630-40.
35. Vitali C, Bombardieri S, Moutsopoulos HM et al. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arhritis Rheum 1993; 36:340-7.
36. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
37. Barnett AJ, Miller MH, Littlejohn GO. A survival study of patients with scleroderma diagnosed over 30 years (1953-83): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 1988; 15:276-83.
38. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979; 66:210-5.
39. Sullivan KE, Wisnieski JJ, Winkelstein JA et al. Serum complement determinations in patients with quiescent systemic lupus erythematosus. J Rheumatol 1996; 23:2063-7.
40. Hebbar M, Lassalle P, Janin A, Vanhée D, Bisiau S, Hatron PY, Tonnel AB, Gosselin B. E-selectin expression in salivary endothelial cells and sera of patients with systemic sclerosis. Role of resident mast cell-derived tumor necrosis factor alpha (TNF α). Arthritis Rheum 1995; 38:406-12.
41. Claman H, Giorno R, Seibold J. Endothelial and fibroblastic activation in scleroderma. The myth of the 'uninvolved' skin. Arthritis Rheum 1991; 34:1495-501.
42. Talal N, Fischbach M, Dauphinee M. Impaired AMLR in autoimmunity. Behring Inst Mitt 1983; 72:169-76.
43. Stekman IL, Blasini AM, Leon-Ponte M, Baroja ML, Abadi I, Rodriguez MA. Enhanced CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus. Arthritis Rheum 1991; 34:459-67.
44. Levental BG, Waldorf DS, Talal N. Impaired lymphocyte transformation and delayed hypersensitivity, in Sjögren's syndrome. J Clin Invest 1967; 46:1338-45.